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Résumé en
anglais
BACKGROUND: Radiofrequency ablation is the recommended treatment for patients
with hepatocellular carcinoma who have lesions smaller than 3 cm and are therefore
not candidates for surgery. Microwave ablation is a more recent technique with
certain theoretical advantages that have not yet been confirmed clinically. We aimed
to compare the efficacy of both techniques in the treatment of hepatocellular
carcinoma lesions of 4 cm or smaller.
METHODS: We did a randomised controlled, single-blinded phase 2 trial at four
tertiary university centres in France and Switzerland. Patients with chronic liver
disease and hepatocellular carcinoma with up to three lesions of 4 cm or smaller who
were not eligible for surgery were randomised to receive microwave ablation
(experimental group) or radiofrequency ablation (control group). Randomisation was
centralised and done by use of a fixed block method (block size 4). Patients were
randomly assigned by a co-investigator by use of the sealed opaque envelope method
and were masked to the treatment; physicians were not masked to treatment, since
the devices used were different. The primary outcome was the proportion of lesions
with local tumour progression at 2 years of follow-up. Local tumour progression was
defined as the appearance of a new nodule with features typical of hepatocellular
carcinoma in the edge of the ablation zone. All analyses were done in the per-protocol
population. The study is completed, but patients will continue to be followed up for 5
years. This study is registered with ClinicalTrials.gov, number NCT02859753.
FINDINGS: Between Nov 15, 2011, and Feb 27, 2015, 152 patients were randomly
assigned: 76 patients to receive microwave ablation and 76 patients to receive
radiofrequency ablation. For the per-protocol analysis, five patients were excluded
from the microwave ablation group as were three patients from the radiofrequency
ablation group. Median follow-up was 26 months (IQR 18-29) in the microwave
ablation group and 25 months (18-34) in the radiofrequency ablation group. At 2
years, six (6%) of 98 lesions had local tumour progression in the microwave ablation
group as did 12 (12%) of 104 in the radiofrequency ablation group (risk ratio 1·62,
95% CI 0·66-3·94; p=0·27). Complications were infrequent, with only two grade 4
complications (two events of arterial bleeding requiring embolisation, both in the
microwave ablation group) and three grade 3 complications (pneumothorax; lesion of
the umbilical vein; and intrahepatic segmental necrosis, all in the radiofrequency
ablation group). No treatment-related deaths were reported.
INTERPRETATION: Although we did not find that microwave ablation was more
effective than radiofrequency ablation for treatment of hepatocellular carcinoma
lesions of 4 cm or smaller, our results show that the proportion of lesions with local
tumour progression at 2 years of follow-up was low with both tested percutaneous
methods.
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